创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

董婧雯, 黄莹, 李全豪, 周占威, 孙敏捷. “冷肿瘤”免疫调节纳米制剂研究进展[J]. 药学进展, 2022, 46(9): 645-657. DOI: 10.20053/j.issn1001-5094.2022.09.002
引用本文: 董婧雯, 黄莹, 李全豪, 周占威, 孙敏捷. “冷肿瘤”免疫调节纳米制剂研究进展[J]. 药学进展, 2022, 46(9): 645-657. DOI: 10.20053/j.issn1001-5094.2022.09.002
DONG Jingwen, HUANG Ying, LI Quanhao, ZHOU Zhanwei, SUN Minjie. Recent Advances of Nano-immunomodulatory for Reversal of Cold Tumor Microenvironment[J]. Progress in Pharmaceutical Sciences, 2022, 46(9): 645-657. DOI: 10.20053/j.issn1001-5094.2022.09.002
Citation: DONG Jingwen, HUANG Ying, LI Quanhao, ZHOU Zhanwei, SUN Minjie. Recent Advances of Nano-immunomodulatory for Reversal of Cold Tumor Microenvironment[J]. Progress in Pharmaceutical Sciences, 2022, 46(9): 645-657. DOI: 10.20053/j.issn1001-5094.2022.09.002

“冷肿瘤”免疫调节纳米制剂研究进展

Recent Advances of Nano-immunomodulatory for Reversal of Cold Tumor Microenvironment

  • 摘要: “冷肿瘤”免疫屏障极大限制了肿瘤免疫疗法的治疗效果。近年来,基于肿瘤免疫学研究的发展,免疫调节纳米制剂展示了其广阔的生物医学应用前景,有望成为精准化免疫治疗领域的新范式。通过对“冷肿瘤”免疫屏障的定义及特征进行简述,重点综述多种免疫调节纳米制剂在“冷肿瘤”治疗中的研究进展,分析讨论免疫调节纳米制剂向临床研究转化存在的技术壁垒,以期为免疫调节纳米制剂在“冷肿瘤”治疗方面的进一步发展提供参考。

     

    Abstract: Tumor immunotherapy is limited by the immunosuppressive barrier of the cold tumor. With years of efforts for the exploration of the tumor immunosuppressive barrier, nano-immunomodulatory has become the new paradigm of application for precise remodeling of tumors to amplify the effect of cancer treatment. The definition and characteristics of tumor are summarized to illustrate how engineered nanoplatforms break immunosuppressive. Furthermore, the translation and bottleneck of nano-immunomodulatory are discussed for enhanced immunotherapy in cold tumor.

     

/

返回文章
返回